Compare CVCO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVCO | LQDA |
|---|---|---|
| Founded | 1965 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 3.8B |
| IPO Year | 1994 | 2020 |
| Metric | CVCO | LQDA |
|---|---|---|
| Price | $605.82 | $45.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $662.00 | $54.38 |
| AVG Volume (30 Days) | 75.6K | ★ 5.5M |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.79 | ★ 51.81 |
| EPS | ★ 5.43 | 1.26 |
| Revenue | ★ $2,142,713,000.00 | $158,320,000.00 |
| Revenue This Year | $9.17 | $357.27 |
| Revenue Next Year | $7.74 | $1.34 |
| P/E Ratio | $100.27 | ★ $35.65 |
| Revenue Growth | 31.68 | ★ 1031.18 |
| 52 Week Low | $443.34 | $22.22 |
| 52 Week High | $713.01 | $93.61 |
| Indicator | CVCO | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 66.18 | 51.26 |
| Support Level | $558.79 | $35.00 |
| Resistance Level | $630.48 | $46.67 |
| Average True Range (ATR) | 21.27 | 2.88 |
| MACD | 6.65 | 2.62 |
| Stochastic Oscillator | 78.83 | 89.61 |
Cavco Industries Inc designs and produces factory-built homes distributed through a network of independent and company-owned retailers, planned community operators and residential developers. It is also a producer of park model RVs, vacation cabins and Factory-built commercial structures. It operates principally in two segments: factory-built housing, which includes wholesale and retail factory-built housing operations and Financial services, which include manufactured housing consumer finance and insurance. The factory-built housing segment generates the majority of revenue from building and selling manufactured and modular homes to both wholesale customers and end consumers through company owned retail stores.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.